Langzhou Song

Summary

Affiliation: VaxInnate Corporation
Country: USA

Publications

  1. ncbi Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
    James W Huleatt
    VaxInnate Corporation, New Haven, CT 06511, USA
    Vaccine 25:763-75. 2007
  2. ncbi Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs
    Langzhou Song
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 3:e2257. 2008
  3. ncbi Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin
    Langzhou Song
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512 0026, USA
    Vaccine 27:5875-84. 2009
  4. ncbi Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
    James W Huleatt
    VaxInnate Corporation, 300 George Street, New Haven, CT 06511, USA
    Vaccine 26:201-14. 2008
  5. ncbi Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
    Ge Liu
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 30:6833-8. 2012
  6. ncbi Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
  7. ncbi Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice
    Ge Liu
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 6:e20928. 2011

Collaborators

Detail Information

Publications7

  1. ncbi Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
    James W Huleatt
    VaxInnate Corporation, New Haven, CT 06511, USA
    Vaccine 25:763-75. 2007
    ..Collectively our data demonstrate that PAMP:antigen fusion proteins offer significant promise for developing recombinant protein vaccines...
  2. ncbi Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs
    Langzhou Song
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 3:e2257. 2008
    ..These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines...
  3. ncbi Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin
    Langzhou Song
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512 0026, USA
    Vaccine 27:5875-84. 2009
    ..We find that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model...
  4. ncbi Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
    James W Huleatt
    VaxInnate Corporation, 300 George Street, New Haven, CT 06511, USA
    Vaccine 26:201-14. 2008
    ..These data demonstrate that the linkage of specific TLR ligand with influenza M2e yields a vaccine candidate that offers significant promise for widespread protection against multiple influenza A virus strains...
  5. ncbi Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
    Ge Liu
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 30:6833-8. 2012
    ..Taken together, our recombinant flagellin-HA platform has been successfully used to generate potent H5N1 HPAIV vaccine candidates. These promising preclinical results justify the advancement of these candidates into the clinic...
  6. ncbi Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
    ..HA1 was fused to the C-terminus of flagellin in VAX128A, replaced the D3 domain of flagellin in VAX128B and was fused in both positions in VAX128C...
  7. ncbi Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice
    Ge Liu
    VaxInnate Corporation, Cranbury, New Jersey, United States of America
    PLoS ONE 6:e20928. 2011
    ..Taken together, the results demonstrate that all three vaccine candidates are highly immunogenic and efficacious in mice, and that the STF2R3.2xHA1 format is the most effective candidate vaccine format...